Shares of Galena Biopharma (GALE +12.9%) are on a tear this morning after reporting a better...
Tuesday, November 13, 2012, 10:59 AM ETShares of Galena Biopharma (GALE +12.9%) are on a tear this morning after reporting a better than anticipated Q3 loss of $0.09 per share, narrower than the prior year's EPS loss of $0.13 and beating the Street consensus for a loss of $0.10. Operating losses decreased Y/Y, largely due to writedown's taken during Q311 due to discontinued operations, which were driven by the company's ongoing, late-stage trial for NeuVax and the spin-off of a pharmaceuticals subsidiary.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles